M&A Transaction Database
Therapeutics M&A Transactions
Mergers and acquisitions in the Therapeutics subsector.
Never miss a transaction
Get instant notifications when new M&A transactions matching "Therapeutics" are published.
Filters
6 shown
Fulcrum Therapeutics
Biotech Merger: Fulcrum & Slate Combine for Migraine TherapiesFulcrum Therapeutics and Slate Medicines merge, creating a new Nasdaq-listed biotech focused on migraine treatments, bolstered by $245 million in new funding.
LEO Pharma secures global rights to dersimelagon, a promising oral therapy for rare skin conditions EPP and XLP, in a deal valued up to $435 million.
Valerio Therapeutics advances its €30 million acquisition of Etherna Immunotherapies, securing regulatory clearance and targeting a late August deal signing.
Jasper Therapeutics
Jasper Therapeutics Acquires Kira Pharmaceuticals, Boosts PipelineJasper Therapeutics merges with Kira Pharmaceuticals, enhancing its immunology pipeline with three key assets and securing $132 million in financing for extended operational runway.
PTC Therapeutics secures ST-920 Fabry gene therapy from Sangamo Therapeutics for up to $211M, enhancing its rare disease treatment portfolio.
Viome Life Sciences acquires Circulate Health, integrating plasma exchange technology to advance its mission in the rapidly growing longevity and healthspan sector.
Never Miss a Deal
Get weekly investment intelligence. Free forever.
You reached the end (6 deals).